SAN

92.05

+0.8%↑

SRT3

229.6

+1.68%↑

BIM

115.6

+0.7%↑

ORNBV.FI

54.9

-0.54%↓

GXI

59.7

+0.93%↑

SAN

92.05

+0.8%↑

SRT3

229.6

+1.68%↑

BIM

115.6

+0.7%↑

ORNBV.FI

54.9

-0.54%↓

GXI

59.7

+0.93%↑

SAN

92.05

+0.8%↑

SRT3

229.6

+1.68%↑

BIM

115.6

+0.7%↑

ORNBV.FI

54.9

-0.54%↓

GXI

59.7

+0.93%↑

SAN

92.05

+0.8%↑

SRT3

229.6

+1.68%↑

BIM

115.6

+0.7%↑

ORNBV.FI

54.9

-0.54%↓

GXI

59.7

+0.93%↑

SAN

92.05

+0.8%↑

SRT3

229.6

+1.68%↑

BIM

115.6

+0.7%↑

ORNBV.FI

54.9

-0.54%↓

GXI

59.7

+0.93%↑

Search

Laboratorios Farmaceuticos Rovi SA

Ouvert

SecteurSoins de santé

53.05 -0.56

Résumé

Variation du prix de l'action

24h

Actuel

Min

52.15

Max

53.35

Chiffres clés

By Trading Economics

Revenu

-57M

32M

Ventes

199M

434M

P/E

Moyenne du Secteur

19.663

54.379

BPA

0.457

Rendement du dividende

2.12

Marge bénéficiaire

7.411

Employés

2,197

EBITDA

40M

138M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+47.53% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

2.12%

2.55%

Prochains Résultats

30 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-719M

2.7B

Ouverture précédente

53.61

Clôture précédente

53.05

Sentiment de l'Actualité

By Acuity

60%

40%

322 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bullish Evidence

Laboratorios Farmaceuticos Rovi SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 mai 2025, 23:59 UTC

Actualités
Résultats

Naver 1Q Net Slumps on Higher Costs

8 mai 2025, 23:39 UTC

Résultats

OCBC 1Q Net Down on Lower Interest Income

8 mai 2025, 23:01 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 mai 2025, 22:52 UTC

Résultats

REA Expects Annual Listings Growth Despite April Decline

8 mai 2025, 22:46 UTC

Résultats

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 mai 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 mai 2025, 23:30 UTC

Résultats

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 mai 2025, 23:29 UTC

Résultats

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 mai 2025, 23:22 UTC

Résultats

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 mai 2025, 23:21 UTC

Résultats

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 mai 2025, 23:17 UTC

Résultats

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 mai 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 mai 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 mai 2025, 23:01 UTC

Actualités

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 mai 2025, 22:28 UTC

Résultats

REA Expects FY 2025 Listings Growth of 1-2%

8 mai 2025, 22:28 UTC

Résultats

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 mai 2025, 22:27 UTC

Résultats

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 mai 2025, 22:27 UTC

Résultats

REA Says April Residential Listings Fell by 11% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 mai 2025, 22:26 UTC

Résultats

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 mai 2025, 22:26 UTC

Résultats

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 mai 2025, 22:25 UTC

Résultats

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Comparaison

Variation de prix

Laboratorios Farmaceuticos Rovi SA prévision

Objectif de Prix

By TipRanks

47.53% hausse

Prévisions sur 12 Mois

Moyen 77.75 EUR  47.53%

Haut 90 EUR

Bas 65.5 EUR

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

51.1 / N/ASupport & Résistance

Court Terme

Weak Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bearish Evidence

Sentiment

By Acuity

322 / 382Classement par Soins de santé

Sentiment de l'Actualité

Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.